Tuberculosis (active / latent)

tuberculosis

← back to Infectious Diseases

Summary

2020 NTCA/CDC update to the 2000 ATS/CDC latent TB infection (LTBI) treatment guidelines, based on GRADE systematic review and network meta-analysis. Short-course (3–4 month) rifamycin-based regimens are now preferred over 6–9 months of isoniazid monotherapy because of equivalent efficacy, lower hepatotoxicity, and higher completion rates. Applies only to LTBI presumed susceptible to isoniazid or rifampin (not MDR-TB contacts).

Current guideline: 2020 NTCA/CDC Latent TB Guideline · download Anki sub-deck

Versions

• 2020 · NTCA/CDC — 2020 NTCA/CDC Latent TB Guideline
  • Read the guideline: html · pmc · Anki deck
• 2016 · ATS/CDC/IDSA — ATS/CDC/IDSA 2016 TB Treatment Guideline
  • Read the guideline: html · pmc

---

Table of contents

• 2020 · NTCA/CDC